Pharmaceutical Research and Manufacturers of America (PhRMA)

The Pharmaceutical Research and Manufacturers of America, commonly known as PhRMA, is a U.S. trade association for research-based pharmaceutical and biopharmaceutical companies. Founded in 1958 and headquartered in Washington, D.C., it represents member companies rather than selling medicines to consumers or operating as a drug manufacturer in its own right. Its work focuses on public policy, government relations, communications, and industry positions concerning the research, development, regulation, coverage, pricing, and use of medicines. PhRMA’s central institutional role is to present the perspectives of its member companies in debates over the U.S. health-care and life-sciences environment. Its advocacy commonly addresses biomedical research and innovation, intellectual property, regulation, insurance coverage, reimbursement, medicine affordability, and patient access. The association also publishes policy material and industry information and communicates arguments about the role of private-sector research in developing new treatments. Its activity is principally U.S.-focused, although the policy and commercial questions it addresses are connected to international pharmaceutical research and markets. PhRMA is a membership-based association, not a publicly traded company; it has no stock ticker or parent corporation. Its membership has included research-based pharmaceutical companies, with participation and membership changing over time. The association is led by a chief executive and governed through its organizational structure and member representation. Stephen J. Ubl has served as PhRMA’s president and chief executive officer since 2015. PhRMA’s public profile is closely tied to the policy positions of the pharmaceutical industry. Its advocacy and communications are therefore part of ongoing public discussion about innovation, medicine costs, intellectual property, and access. It should be distinguished from individual drug companies and from medicines sold under commercial product brands: PhRMA represents industry interests and engages in policy advocacy rather than marketing a consumer product portfolio.

PhRMA was established in 1958 as an organization for the research-based pharmaceutical industry in the United States. It developed as a membership association representing companies engaged in discovering and developing medicines, rather than as a manufacturer or a commercial drug brand. From its base in Washington, D.C., the organization became a participant in policy debates involving pharmaceutical research, medicine regulation, health-care coverage, and the conditions under which new medicines reach patients. Over its history, the association’s remit has reflected changes in both the pharmaceutical sector and U.S. health policy. The expansion of biomedical research and the increasing complexity of drug development brought questions of research incentives, intellectual property, clinical evidence, and regulation into greater public and political focus. PhRMA has represented member-company views on these topics through government relations, public policy proposals, industry information, and communications. Its advocacy has also engaged with questions concerning medicine affordability, insurance coverage, reimbursement, and patient access—issues that bring the interests of manufacturers into contact with those of patients, health plans, providers, public programs, and policymakers. As a trade association, PhRMA’s membership and organizational priorities have evolved over time. It speaks for participating research-based pharmaceutical companies, while individual member companies remain separate businesses with their own products, leadership, and commercial strategies. The association itself does not own a unified portfolio of medicines and is not a public company. Its influence and public visibility derive primarily from its role in policy advocacy and from its communications about the pharmaceutical research enterprise. In the contemporary policy environment, PhRMA continues to focus on the conditions for biomedical innovation and the development, regulation, coverage, and accessibility of medicines. Its positions are part of contested public debates, particularly around drug prices, affordability, intellectual property, and the balance between incentives for research and access to treatment. The organization’s identity is consequently best understood as an industry representative and policy advocate, not as a pharmaceutical manufacturer or a patient-facing health-care provider. Stephen J. Ubl has served as president and chief executive officer since 2015.

• 2015

  Stephen J. Ubl becomes president and CEO

• 1958

  PhRMA established

A Washington-based industry association representing research-based biopharmaceutical companies, with a policy and advocacy role rather than a consumer-facing product business.

• Policy advocacy and government relations

  Representation of member-company perspectives in public policy and government discussions affecting pharmaceutical research and medicines.

• Industry policy research and publications

  Policy analysis and information about pharmaceutical research, innovation, regulation, and access.

• 2026

  PhRMA sues to block CMS GLOBE most-favored-nation drug pricing model for Medicare Part B

  The Pharmaceutical Research and Manufacturers of America (PhRMA) filed a lawsuit in the US District Court for the District of Columbia challenging the CMS Global Benchmark for Efficient Drug Pricing (GLOBE) model, a mandatory "most favored nation" pricing policy for Medicare Part B set to take effect on January 1, 2027. PhRMA alleges that GLOBE is unlawful and exceeds CMS's statutory authority, that the agency is using limited demonstration model authority to impose nationwide price-setting policies Congress never authorized, and that benchmarks relying on quality-adjusted life-years can discriminate against people with disabilities, chronic conditions, and rare diseases. The lawsuit asks the court to declare GLOBE unlawful and vacate the rule in its entirety.

  Source

Read more

1. 1PhRMA official websitephrma.org
2. 2Pharmaceutical Research and Manufacturers of Americaen.wikipedia.org
3. 3PhRMA sues to block CMS GLOBE most-favored-nation drug pricing model for Medicare Part Bajmc.com